Aankondiging • Jun 30

Abivax Reports Positive Abtect Maintenance Part 2 Results for Obefazimod in Refractory Ulcerative Colitis Patients

Abivax announced topline results from ABTECT Maintenance Part 2, the supplemental portion of its Phase 3 UC maintenance program evaluating obefazimod, its investigational oral miR-124 enhancer, in adults with moderately to severely active UC. Part 2 of the Phase 3 Maintenance trial enrolled patients who either did not achieve clinical response following induction treatment or who experienced disease relapse during the re-randomized maintenance trial (Part 1), expanding both the efficacy and safety results in a more refractory patient population than the registrational maintenance cohort. The additional safety results generated through Part 2 expand the Phase 3 maintenance database and provide important context for interpreting the safety findings reported following the Maintenance Part 1 readout. The integrated post-hoc analyses presented include the new Part 2 results, the combined Phase 3 maintenance program, and the broader Phase 2 and Phase 3 clinical development program. Obefazimod delivered meaningful clinical benefit in a highly refractory ulcerative colitis population, with 37.2% of induction non-responders achieving clinical remission and 34.5% achieving endoscopic remission at Week 44 following continued 50 mg treatment. Dose escalation to obefazimod 50 mg recaptured clinical remission in 45.5% of patients who relapsed during ABTECT Maintenance Part 1, supporting a practical dose-escalation strategy for regaining and sustaining disease control over time. Across the integrated Phase 2 and Phase 3 UC program (1,704 patient-years of exposure), exposure-adjusted incidence rates for malignancies excluding non-melanoma skin cancer were 0.35 and 0.64 events per 100 patient-years, and for non-melanoma skin cancer were 0.59 and 0.64 events per 100 patient-years in the all-active combined (50 mg + 25 mg) and 50 mg cohorts respectively, all consistent with expected UC background rates. In ABTECT Maintenance Part 2, exposure-adjusted incidence rates for malignancies excluding non-melanoma skin cancer were 0.48 and 0.69 events per 100 patient-years, and for non-melanoma skin cancer were 0.95 and 0.69 events per 100 patient-years, in the all-active combined and 50 mg cohorts respectively, all consistent with expected UC background rates. Among patients who failed to achieve clinical response after 8 weeks of induction, continued treatment with obefazimod resulted in clinically meaningful rates of clinical, endoscopic, and combined histologic-endoscopic endpoints at Week 44. Patients treated continuously with 50 mg obefazimod demonstrated the strongest outcomes across all endpoints, including clinical remission (37.2%), clinical response (61.5%), endoscopic improvement (48.0%), Histologic-Endoscopic Mucosal Improvement (44.6%), and endoscopic remission (34.5%). Among patients who relapsed during Maintenance Part 1, re-treatment with 50 mg obefazimod resulted in clinically meaningful rates of clinical remission, clinical response, endoscopic improvement, Histologic-Endoscopic Mucosal Improvement and endoscopic remission by Week 44. Patients who achieved clinical response with obefazimod during induction and relapsed after being re-randomized to placebo in Part 1 of the maintenance trial were treated with open-label 50 mg obefazimod and achieved clinical response and remission rates of 69.7% and 45.0%, respectively, while patients who relapsed on 25 mg and escalated to 50 mg achieved clinical response and remission rates of 66.7% and 45.5%, respectively. The post-hoc analyses below are presented progressively, from the combined Phase 2 and Phase 3 UC programs to the Phase 3 maintenance dataset (Part 1 + Part 2), and then to the Part 2 maintenance dataset, to illustrate how increasing cumulative patient-years strengthens the overall safety assessment. In Part 2, four total non-melanoma skin cancer events were reported, two in the 25 mg arm and two in the 50 mg arm, which all occurred in patients with established non-melanoma skin cancer risk factors including advanced age, thiopurine use, prior skin cancer history and failure of multiple prior advanced therapies. There were also two non-non-melanoma skin cancer malignancies reported in the 50 mg arm, both deemed unrelated to obefazimod by the study investigators. Because non-melanoma skin cancers and malignancies excluding non-melanoma skin cancers are uncommon events, incidence-rate estimates become more precise as cumulative exposure increases. The ABTECT Maintenance data should be interpreted using the totality of the exposure-adjusted evidence, together with patient characteristics and representative published UC epidemiologic reference ranges. The results in the tables below demonstrate that the exposure-adjusted incidence rate in the combined all active (25 mg + 50 mg) treatment arms for both non-melanoma skin cancers and malignancies excluding non-melanoma skin cancers are within the UC background reference range based on published UC studies. Malignancies (Excluding NMSC) – EAIR Analysis: Integrated UC Program (Phase 2 + Phase 3): Placebo IR/100 PY 0.00, 25 mg IR/100 PY 0.00, 50 mg IR/100 PY 0.64, All Active IR/100 PY 0.35, Expected UC Background 0.30 – 0.70. Phase 3 Maintenance (Part 1 + Part 2): Placebo IR/100 PY 0.00, 25 mg IR/100 PY 0.00, 50 mg IR/100 PY 0.91, All Active IR/100 PY 0.56, Expected UC Background 0.30 – 0.70. Part 2 Only: 25 mg IR/100 PY 0.00, 50 mg IR/100 PY 0.69, All Active IR/100 PY 0.48, Expected UC Background 0.30 – 0.70. NMSC – EAIR Analysis: Integrated UC Program (Phase 2 + Phase 3): Placebo IR/100 PY 0.46, 25 mg IR/100 PY 0.53, 50 mg IR/100 PY 0.64, All Active IR/100 PY 0.59, Expected UC Background 0.70 – 1.40. Phase 3 Maintenance (Part 1 + Part 2): Placebo IR/100 PY 0.68, 25 mg IR/100 PY 1.09, 50 mg IR/100 PY 1.37, All Active IR/100 PY 1.26, Expected UC Background 0.70 – 1.40. Part 2 Only: 25 mg IR/100 PY 1.52, 50 mg IR/100 PY 0.69, All Active IR/100 PY 0.95, Expected UC Background 0.70 – 1.40. The overall safety results observed in Part 2 were consistent with those previously observed in the broader obefazimod clinical development program. No new safety pattern emerged with the additional cumulative exposure provided by Part 2. Detailed exposure-adjusted analyses by trial, dose, cumulative patient-years, and patient characteristics will be presented during the investor webcast. The ABTECT Maintenance Part 2 results expand the integrated clinical dataset supporting the planned New Drug Application for obefazimod in UC. The Company remains on track to submit its New Drug Application to the U.S. Food and Drug Administration in the fourth quarter of 2026. Next anticipated key milestones: September 21, 2026 – Half-year 2026 financial results; Fourth Quarter 2026 – Planned New Drug Application submission for obefazimod in UC; Mid-2027 – Topline results from the Phase 2b ENHANCE-CD induction trial evaluating obefazimod in Crohn's disease.

Totaal aandeelhoudersrendement	-6.9%
Toekomstig dividendrendement	0%
Dividendgroei	n/a
Volgende betaaldatum dividend	n/a
Ex-dividenddatum	n/a
Dividend per aandeel	n/a
Uitbetalingsratio	n/a

Segment	Dividendrendement
Bedrijf (ABVX)	n/a
Markt onderkant 25% (US)	1.3%
Markt Top 25% (US)	4.0%
Gemiddelde industrie (Biotechs)	2.0%
Analist prognose (ABVX) (tot 3 jaar)	0%

Gegevens	Laatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse	2026/08/07 08:24
Aandelenkoers aan het einde van de dag	2026/08/06 00:00
Inkomsten	2026/03/31
Jaarlijkse inkomsten	2025/12/31

Pakket	Gegevens	Tijdframe	Voorbeeld Amerikaanse bron ^*
Financiële gegevens bedrijf	10 jaar	Resultatenrekening Kasstroomoverzicht Balans	SEC-formulier 10-K SEC-formulier 10-Q
Consensus schattingen analisten	+3 jaar	Financiële prognoses Koersdoelen analisten	Onderzoeksrapporten van analisten Blue Matrix
Marktprijzen	30 jaar	Aandelenprijzen Dividenden, splitsingen en acties	ICE Marktgegevens SEC-formulier S-1
Eigendom	10 jaar	Top aandeelhouders Handel met voorkennis	SEC-formulier 4 SEC-formulier 13D
Beheer	10 jaar	Leiderschapsteam Raad van bestuur	SEC-formulier 10-K SEC-formulier DEF 14A
Belangrijkste ontwikkelingen	10 jaar	Bedrijfsaankondigingen	SEC-formulier 8-K

Analist	Instelling
Etzer Darout	Barclays
Julian Harrison	BTIG
Jason Butler	Citizens JMP Securities, LLC

ABIVAX Société Anonyme Dividenden en inkoop

Dividend criteriumcontroles 0/6

Belangrijke informatie

Recente updates van dividend en inkoop

Recent updates

Abivax Announces Positive Pre-NDA Interaction With FDA For Obefazimod

Abivax SA Announces Executive Appointments

Abivax: Obefazimod Goes The Distance And So Does My Buy Rating

Valerio Therapeutics Enters into Binding Term-Sheet with Abivax for Exclusive Global Research and Development Collaboration and Provides Pipeline Update

ABIVAX Société Anonyme has completed a Follow-on Equity Offering in the amount of $800 million.

ABIVAX Société Anonyme has filed a Follow-on Equity Offering in the amount of $600 million.

Abivax Reports Positive Abtect Maintenance Part 2 Results for Obefazimod in Refractory Ulcerative Colitis Patients

Abivax Reports Landmark Phase 3 Abtect Maintenance Trial Results Evaluating Obefazimod in Moderately to Severely Active Ulcerative Colitis

ABIVAX Société Anonyme, Annual General Meeting, May 11, 2026

ABIVAX Société Anonyme Announces Board and Management Changes

Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease At Ecco 2026

ABIVAX Société Anonyme to Report First Half, 2026 Results on Sep 14, 2026

ABIVAX Société Anonyme to Report Fiscal Year 2025 Results on Mar 23, 2026

Abivax SA Presents 22 Abstracts On Obefazimod In Inflammatory Bowel Disease At ECCO 2026 Including Oral Presentation On Preclinical Anti-Fibrotic Findings

Abivax SA Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced Therapies

ABIVAX Société Anonyme has completed a Follow-on Equity Offering in the amount of $649.984 million.

ABIVAX Société Anonyme has filed a Follow-on Equity Offering in the amount of $400 million.

Abivax Announces Positive Phase 3 Results from Both ABTECT 8-Week Induction Trials Investigating Obefazimod, Its First-In-Class Oral miR-124 Enhancer, in Moderate to Severely Active Ulcerative Colitis

Abivax Sa Announces Completion of Enrollment for the Phase 3 Abtect Trials in Patients with Moderately to Severely Active Ulcerative Colitis

Abivax SA Appoints Dominik Höchli to the Board of Directors

ABIVAX: Undercovered, Late-Stage French Company With Upcoming Catalysts

ABIVAX Société Anonyme, Annual General Meeting, Jun 06, 2025

ABIVAX Société Anonyme to Report Q1, 2025 Results on Jun 02, 2025

Abivax Achieves Key Milestone in Phase 3 ABTECT Trial Enrollment

Abivax SA Announces Resignation of Philippe Pouletty as Director, Effective December 31, 2024

ABIVAX Société Anonyme has filed a Follow-on Equity Offering in the amount of €150 million.

Abivax SA Announces Board Observer & Advisor Appointments

Abivax SA Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn's Disease

Abivax SA Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25Mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2- Years of Open-Label Maintenance

Abivax SA Provides Updates on Ongoing Clinical Trials

Abivax SA Announces Presentation of Four Abstracts for Obefazimod in Ulcerative Colitis and Preclinical Colon Cancer Model At Digestive Disease Week 2024

ABIVAX Société Anonyme Appoints Ana Sharma as Global Head of Quality

Abivax Announces Update to Obefazimod Phase 2B Clinical Development Program in Moderately to Severely Active Crohn’s Disease

Abivax to Host KOL Investor Event to Review Phase 2B Clinical Data and Phase 3 Trial Design for Obefazimod in Patients with Moderately to Severely Active Ulcerative Colitis

ABIVAX Société Anonyme to Report Fiscal Year 2023 Results on Apr 02, 2024

ABIVAX Société Anonyme has filed an IPO in the amount of $100 million.

Stabiliteit en groei van betalingen

Dividendrendement versus markt

Winstuitkering aan aandeelhouders

Contante uitbetaling aan aandeelhouders

Ontdek bedrijven met een sterk dividend

Bedrijfsanalyse en status van financiële gegevens

Gegevensbronnen

Analysemodel en Snowflake

Industrie en sector

Bronnen van analisten